Moderna(@moderna_tx):Today, along with the University of Oxford, we announced that a Phase 1/2 study of mRNA-4194, our investigational cancer vaccine for Lynch syndrome, has received Medicines and Healthcare products Regulatory Agency (MHRA) authorization in the UK. The trial is part of a scientific collaboration between Moderna and the University of Oxford to advance a novel mRNA approach to cancer prevention. Read more:

Moderna

@moderna_tx

Our mission is to deliver the greatest possible impact to people through mRNA medicines.

加入 December 2013

541 正在關注 145.4K 粉絲

Moderna@moderna_tx

2026.06.08 23:06

Today, along with the University of Oxford, we announced that a Phase 1/2 study of mRNA-4194, our investigational cancer vaccine for Lynch syndrome, has received Medicines and Healthcare products Regulatory Agency (MHRA) authorization in the UK. The trial is part of a scientific collaboration between Moderna and the University of Oxford to advance a novel mRNA approach to cancer prevention. Read more: